NervGen Pharma Appoints Bill Radvak as Interim CEO
NervGen Pharma (OTCQX:NGENF) notifies that the board and Paul Brennan have mutually agreed that Mr. Brennan will step down as President & CEO and a member of the board, effective immediately. The
NervGen Pharma GAAP EPS of -$0.13
NervGen Pharma press release (OTCQX:NGENF): Q2 GAAP EPS of -$0.13. Cash position enhanced by over $22M.
NervGen Pharma GAAP EPS of -$0.11
NervGen Pharma press release (OTCQX:NGENF): Q1 GAAP EPS of -$0.11.NervGen had cash and investments of $12.8 million as of March 31, 2022, compared to $5.0 million as of March 31, 2021. The net cash
NervGen Pharma gets safety panel nod to advance in phase 1 trial of NVG-291
NervGen Pharma (OTCQX:NGENF) received approval from A safety review committee to advance to the second cohort in the multiple ascending dose (MAD) portion of its phase 1 trial of NVG-291. The company
NervGen Pharma Closes $9.2 Million Bought Deal Financing
10:46 AM EST, 11/12/2021 (MT Newswires) -- NervGen Pharma Corp. (NGEN.V), a clinical-stage biotech company, said Friday that it has completed a $9.2 million bought deal financing. This included the f
NervGen Pharma Upsizes Bought Deal Financing; Falls 11.1%
01:51 PM EDT, 11/05/2021 (MT Newswires) -- NervGen Pharma Corp., (NGEN.V), a clinical-stage biotech company, said Friday that it has increased the size of its $5 million bought deal offering. Under t
Industrial Alliance Initiates Coverage On NervGen Pharma with Speculative Buy Rating, Announces Price Target of $6
Industrial Alliance initiates coverage on NervGen Pharma (OTC:NGENF) with a Speculative Buy rating and announces Price Target of $6.
NervGen Pharma analyst ratings
DateResearch FirmActionCurrentPT 7/13/21Industrial AllianceInitiates Coverage OnSpeculative Buy6.0